Overview


According to FutureWise analysis the market for Iodine Deficiency Drug in 2023 is US$ 4.16 billion, and is expected to reach US$ 6.64 billion by 2031 at a CAGR of 6.02%.

Iodine deficiency disorders refer to a group of health problems that occur as a result of insufficient iodine intake. It is a rare endocrinology disorder in which the thyroid gland in the neck produces inadequate amounts or is unable to produce thyroid hormone as a result of a deficiency of iodine, an essential nutrient required for thyroid development. Among other things, thyroid hormone regulates body temperature, metabolism, and heart rate. There are many adverse effects associated with iodine deficiency, from abortion to stillbirth to mental retardation and deafness. These problems are collectively known as Iodine Deficiency Disorders (IDDs). It is a rare form of endocrinology where the thyroid gland in the neck does not produce thyroid hormone or is incapable of producing it due to a deficiency of iodine, which is an essential nutrient required for the thyroid gland to function properly. In addition to regulating body temperature, metabolism, and heart rate, thyroid hormone is responsible for the body's survival. Patients with iodine deficiency experience abnormal brain development, mental retardation, psychomotor defects, and hearing and speech impairments. The halogen element iodine has the atomic number 53 in group seven of the periodic table. This chemical is blue-black in color, has a lustrous sheen, and comes in various chemical forms, including iodate, iodide, and elemental iodine. The most common form of it is the diatomic molecule I2. Seawater contains abundant iodine, but it is distributed unevenly throughout the oceans and on land. In industry, iodine derivatives are widely used as chemical intermediaries. Mental retardation, goiter, vision problems, heart diseases, and intellectual disabilities are caused by iodine deficiency in humans and animals. Since it has a relatively low toxicity and a high atomic number, iodine is widely used as a contrast agent in X-ray media. Aside from its use as a catalyst in industrial chemical reactions and biocides, iodine is also used in animal nutrition and as a contrast agent in LED polarizing films. Health problems caused by iodine deficiency disorders are caused by a diet that is deficient in iodine. This is a rare endocrinology disorder in which the thyroid gland in the neck produces insufficient amounts or cannot produce thyroid hormone due to a lack of iodine, an essential nutrient for thyroid function and growth. As well as controlling body temperature and metabolism, thyroid hormones are also responsible for controlling heart rate. Many problems are associated with Iodine Deficiency Disorders (IDDs), including miscarriage, stillbirth, mental retardation, and hearing impairment.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Iodine Deficiency Drug Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Iodine Deficiency Drug Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Sanofi
  • Johnson & Johnson
  • Biotex Inc
  • Apitope Technology Ltd
  • Novartis AG
  • Immunovant Inc
  • Abbott
  • Bayer AG
  • ILDONG PHARMACEUTICAL Co., Ltd
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Titan Pharmaceuticals Inc
  • Synthonics Inc
  • Genexine Inc
  • Lupin Pharmaceuticals Inc
  • Alvogen
  • AbbVie Inc
  • King Pharma
  • fresenius Kabi AG
  • Mylan N.V.
  • F.Hoffmann La Roche Ltd
  • Lilly
  • Pfizer Inc
  • Novo Nordisk A/S
  • AstraZeneca
  • AStellas Pharma Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Route of Administration Type

  • Medication
  • Surgery
  • Radioactive Iodine
  • Iodine Supplements

By Dosage Form

  • Tablet
  • Capsule
  • Solution
  • Powder
  • Others

By Route of Administration

  • Oral
  • Injectable

By End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Iodine Deficiency Drug Market By Route of Administration Type, By Dosage Form, By Route of Administration, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Iodine Deficiency Drug Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Iodine Deficiency Drug Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Iodine Deficiency Drug Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Iodine Deficiency Drug Market, By Route of Administration Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Medication
        2. Surgery
        3. Radioactive Iodine
        4. Iodine Supplements

  • 8.   Iodine Deficiency Drug Market, By Dosage Form Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tablet
        2. Capsule
        3. Solution
        4. Powder
        5. Others

  • 9.   Iodine Deficiency Drug Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Injectable

  • 10.   Iodine Deficiency Drug Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others

  • 11.   North America Iodine Deficiency Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Iodine Deficiency Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Iodine Deficiency Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Iodine Deficiency Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •        1. Sanofi
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Johnson & Johnson
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Biotex Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Apitope Technology Ltd
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Immunovant Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Abbott
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Bayer AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. ILDONG PHARMACEUTICAL Co., Ltd
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GlaxoSmithKline Plc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Merck KGaA
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Titan Pharmaceuticals Inc
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Synthonics Inc
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Genexine Inc
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Lupin Pharmaceuticals Inc
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. Alvogen
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
          17. AbbVie Inc
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17. 5. Strategic Overview
         18. King Pharma
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
         19. fresenius Kabi AG
          19.1. Company Overview
          19.2. Product Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
        20. Mylan N.V.
          20.1. Company Overview
          20.2. Product Portfolio
          20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview
         21. F.Hoffmann La Roche Ltd
          21.1. Company Overview
          21.2. Product Portfolio
          21.3. SWOT Analysis
          21.4. Financial Overview
          21.5. Strategic Overview
         22. Lilly
          22.1. Company Overview
          22.2. Product Portfolio
          22.3. SWOT Analysis
          22.4. Financial Overview
          22.5. Strategic Overview
         23. Pfizer Inc
          23.1. Company Overview
          23.2. Product Portfolio
          23.3. SWOT Analysis
          23.4. Financial Overview
          23.5. Strategic Overview
         24. Novo Nordisk A/S
          24.1. Company Overview
          24.2. Product Portfolio
          24.3. SWOT Analysis
          24.4. Financial Overview
          24.5. Strategic Overview
         25. AstraZeneca
          25.1. Company Overview
          25.2. Product Portfolio
          25.3. SWOT Analysis
          25.4. Financial Overview
          25.5. Strategic Overview
         26. AStellas Pharma Inc
          26.1. Company Overview
          26.2. Product Portfolio
          26.3. SWOT Analysis
          26.4. Financial Overview
          26.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients